1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Undifferentiated Carcinoma: new trials by email Literature Review of Undifferentiated Carcinoma trials Research Report on Undifferentiated Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Docetaxel - Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1052 | 2007-12-06 | 2025-12-30 |
Adenocarcinoma, Clear Cell (1) · Adenocarcinoma, Mucinous (1) · Brenner Tumor (1) · Carcinoma (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Adenocarcinoma (1) · Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Connective Tissue (1)
Bevacizumab (1) · Carboplatin (1) · Disulfides (1) · Docetaxel (1) · Gemcitabine (1) · Immunoglobulin G (1) · Paclitaxel (1) · Taxes (1)
National Cancer Institute (NCI) (1)
Japan (1) · South Korea (1) · United States (1)
Robert L Coleman (1)
PMID 28438473, PMID 31722153, PMID 37185961
U10CA027469 (1), U10CA180868 (1)